Physician profile
Richard Bunt
NPI 1376619072
$23,912.89
in general payments reported to CMS, 2019-2025
27 companies · $3,134 in 2025
The $3,134 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $553 · 2021: $242 · 2022: $696 · 2023: $1,019 · 2024: $1,342 · 2025: $3,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,785 · Travel and Lodging: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,785.02 |
| Travel and Lodging | $1,709.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16,177.58 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $2,243.90 | 2022-2025 | Ingrezza |
| Abbvie INC. | $1,894.15 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $526.70 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $398.96 | 2019-2025 | Trintellix |
| Lundbeck LLC | $369.54 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $366.68 | 2022-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $328.59 | 2019-2020 | |
| Neuronetics, INC. | $248.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $204.92 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $191.79 | 2019-2025 | Fanapt, Hetlioz |
| Orexo US, INC. | $175.82 | 2020-2024 | Zubsolv |
| Indivior INC. | $143.22 | 2019-2020 | |
| Axsome Therapeutics, INC. | $135.61 | 2023-2025 | Auvelity |
| Tris Pharma INC | $115.26 | 2022-2024 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $99.52 | 2019 | |
| Avanir Pharmaceuticals, INC. | $85.14 | 2019 | |
| Supernus Pharmaceuticals, INC. | $45.03 | 2022-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $28.02 | 2025 | Austedo Xr |
| Almatica Pharma LLC | $25.13 | 2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $19.49 | 2019 | |
| Adlon Therapeutics L.P. | $18.90 | 2019 | |
| Alkermes, INC. | $18.22 | 2021 | |
| Neos Therapeutics, LP | $17.20 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.63 | 2025 | Quviviq |
| Arbor Pharmaceuticals, INC. | $12.20 | 2019 | |
| Corium, LLC | $8.57 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.